Liraglutide weight loss plateaus: what the data actually says

What did @itsshenan actually say?

Two months into liraglutide, she's stalled. She's been eating under 1,200 calories, cycling between 900 and 1,400 calories on different days, hitting her protein and fiber targets, drinking water, and the scale hasn't moved. She's down 50 pounds total and sitting at 183 lbs. She wishes she could switch to tirzepatide but says her bank account won't allow it.

Let's be clear about what she's describing: a textbook weight loss plateau on a GLP-1 receptor agonist, combined with a calorie intake that's low enough to raise some flags. She's not panicking, she's not doing anything extreme, and she's being honest about where she is. That counts for something in a space full of people overclaiming results.

Does the science back this up?

Yes, plateaus on liraglutide are well-documented, and they tend to hit earlier and harder than on newer GLP-1 medications. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) showed that most weight loss on liraglutide 3.0 mg occurs in the first 16-20 weeks, with significant slowing after that. This isn't a personal failure. It's pharmacology.

What makes liraglutide different from tirzepatide or semaglutide is the mechanism. Liraglutide is a single agonist, hitting only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors, which appears to produce meaningfully greater weight loss in head-to-head data. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide achieving up to 22.5% body weight reduction at the highest dose, compared to roughly 5-8% in the SCALE trials for liraglutide. Her instinct to wonder about tirzepatide is not unfounded.

What did they get wrong (or right)?

She got the plateau part right. She got the tirzepatide comparison roughly right. Where things get complicated is the calorie cycling between 900 and 1,400 calories.

Eating at 900 calories is genuinely low. There is real evidence that severe caloric restriction triggers adaptive thermogenesis, where your body reduces its resting metabolic rate to compensate. Rosenbaum and Leibel (2010, New England Journal of Medicine) documented this metabolic adaptation in detail, showing that the body actively defends against weight loss in ways that persist long after the diet ends. Cycling down to 900 calories might feel like escalating effort, but it could be compounding the plateau by triggering metabolic adaptation rather than breaking through it.

Her protein focus is smart. Higher protein intakes during caloric restriction help preserve lean mass, which protects metabolic rate. She's doing that part right. But "under 1,200 calories" combined with 900-calorie days on a GLP-1 medication that already suppresses appetite is something worth discussing with a prescriber, not just managing alone based on TikTok comments.

What should you actually know?

Liraglutide plateaus are real and expected. The drug produces less total weight loss than semaglutide or tirzepatide, and the plateau tends to arrive faster. If you're on liraglutide and you've stalled after losing a meaningful amount of weight, that's not a sign you're doing something wrong. It may be a sign you've hit the ceiling of what this particular medication can do for you.

Calorie cycling at very low intakes is not a proven plateau-breaking strategy. The evidence on adaptive thermogenesis suggests it can backfire. A more evidence-supported approach to a plateau includes resistance training to preserve or rebuild lean mass, a diet break at maintenance calories for 1-2 weeks (as studied by Byrne et al., 2018, International Journal of Obesity), and a conversation with your prescriber about whether dose optimization or a medication change is appropriate.

Switching to tirzepatide is a legitimate clinical conversation, not just a wish. Providers can assess whether it's medically appropriate. The cost barrier she mentioned is real, but compounded options exist in some markets. Those compounded versions are not equivalent to brand-name Mounjaro or Zepbound, and anyone considering them should understand that distinction before making a decision.

Bottom line on this video

This is an honest, grounded update from someone who is managing her expectations well and doing a lot of things right. The science confirms her plateau is expected. The concern is the very low calorie intake, which may be working against her rather than for her. Talking to her prescriber about this, not just adjusting calories on her own, would be the right next step.